Harshman L - Search Results

1

Phase II Study of Pazopanib and Paclitaxel in Patients With Refractory Urothelial Cancer.

Narayanan S, Lam A, Vaishampayan U, Harshman L, Fan A, Pachynski R, Poushnejad S, Haas D, Li S, Srinivas S. Narayanan S, et al. Among authors: harshman l. Clin Genitourin Cancer. 2016 Oct;14(5):432-437. doi: 10.1016/j.clgc.2016.03.011. Epub 2016 Mar 12. Clin Genitourin Cancer. 2016. PMID: 27068017 Free PMC article. Clinical Trial.

2

Current status of cytoreductive nephrectomy in metastatic renal cell carcinoma.

Harshman LC, Srinivas S. Harshman LC, et al. Expert Rev Anticancer Ther. 2007 Dec;7(12):1749-61. doi: 10.1586/14737140.7.12.1749. Expert Rev Anticancer Ther. 2007. PMID: 18062749 Review.

3

Continuous daily dosing of sunitinib in patients with metastatic renal cell cancer.

Harshman L, Srinivas S. Harshman L, et al. Onkologie. 2008 Sep;31(8-9):432-3. doi: 10.1159/000144179. Epub 2008 Aug 12. Onkologie. 2008. PMID: 18787349 Free article. No abstract available.

4

The combination of thalidomide and capecitabine in metastatic renal cell carcinoma -- is not the answer.

Harshman LC, Li M, Srinivas S. Harshman LC, et al. Am J Clin Oncol. 2008 Oct;31(5):417-23. doi: 10.1097/COC.0b013e318168ef47. Am J Clin Oncol. 2008. PMID: 18838876 Clinical Trial.

5

Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib.

Harshman LC, Srinivas S, Kamaya A, Chung BI. Harshman LC, et al. Nat Rev Urol. 2009 Jun;6(6):338-43. doi: 10.1038/nrurol.2009.84. Nat Rev Urol. 2009. PMID: 19498412

6

Increased hemoglobin associated with VEGF inhibitors in advanced renal cell carcinoma.

Harshman LC, Kuo CJ, Wong BY, Vogelzang NJ, Srinivas S. Harshman LC, et al. Cancer Invest. 2009 Oct;27(8):851-6. doi: 10.1080/07357900902744528. Cancer Invest. 2009. PMID: 19603304

7

A phase II study of docetaxel and oxaliplatin for second-line treatment of urothelial carcinoma.

Srinivas S, Harshman LC. Srinivas S, et al. Chemotherapy. 2009;55(5):321-6. doi: 10.1159/000230695. Epub 2009 Jul 27. Chemotherapy. 2009. PMID: 19641314 Free PMC article. Clinical Trial.

8

Ribonucleotide reductase subunit M1 expression in resectable, muscle-invasive urothelial cancer correlates with survival in younger patients.

Harshman LC, Bepler G, Zheng Z, Higgins JP, Allen GI, Srinivas S. Harshman LC, et al. BJU Int. 2010 Dec;106(11):1805-11. doi: 10.1111/j.1464-410X.2010.09327.x. BJU Int. 2010. PMID: 20438561 Free PMC article.

9

The bevacizumab experience in advanced renal cell carcinoma.

Harshman LC, Srinivas S. Harshman LC, et al. Onco Targets Ther. 2010 Oct 5;3:179-89. doi: 10.2147/ott.s8157. Onco Targets Ther. 2010. PMID: 21049084 Free PMC article.

10

Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC).

Harshman LC, Yu RJ, Allen GI, Srinivas S, Gill HS, Chung BI. Harshman LC, et al. Urol Oncol. 2013 Apr;31(3):379-85. doi: 10.1016/j.urolonc.2011.01.005. Epub 2011 Feb 25. Urol Oncol. 2013. PMID: 21353796

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

282 results

Search Page

Filters